


PRODUCT INFORMATION



Fexinidazole

Item No. 18393

CAS Registry No.: 59729-37-2
Formal Name: 1-methyl-2-[[4-(methylthio)phenoxy]methyl]-5-nitro-1H-imidazole
Synonym: HOE239
MF: C₁₂H₁₃N₃O₃S
FW: 279.3
Purity: ≥98%
UV/Vis.: λ_{max}: 227, 257, 299 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fexinidazole is supplied as a crystalline solid. A stock solution may be made by dissolving the fexinidazole in the solvent of choice, which should be purged with an inert gas. Fexinidazole is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of fexinidazole in these solvents is approximately 0.2, 10, and 20 mg/ml, respectively.

Fexinidazole is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, fexinidazole should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Fexinidazole has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Fexinidazole is an antiparasitic agent.¹ It is active against 15 strains of *T. brucei*, including *T. b. rhodesiense*, *T. b. brucei*, and *T. b. gambiense* (IC₅₀s = 0.95-3.31 μM). Fexinidazole inhibits the growth of *L. donovani* at the promastigote and axenic amastigote stages (EC₅₀s = 5.6 and 2.8 μM, respectively).² Fexinidazole (50 to 30 mg/kg per day) reduces parasitic burden and increases survival in a mouse model of infection with benznidazole-susceptible, -partially resistant, or -resistant *T. cruzi*.³ Formulations containing fexinidazole have been used in the treatment of African sleeping sickness and Chagas disease.

References

1. Kaiser, M., Bray, M.A., Cal, M., *et al.* Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. *Antimicrob. Agents Chemother.* **55(12)**, 5602-5608 (2011).
2. Wyllie, S.G., Patterson, S., Stojanovski, L., *et al.* The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. *Sci. Transl. Med.* **4(119)**, 119re1 (2012).
3. Bahia, M.T., de Andrade, I.M., Martins, T.A.F., *et al.* Fexinidazole: A potential new drug candidate for Chagas disease. *PLoS Negl. Trop. Dis.* **6(11)**, e1870 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM